Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

445P - Survival among patients cured from gastric adenocarcinoma compared to the background population

Date

27 Jun 2024

Session

Poster Display session

Presenters

Wilhelm Leijonmarck

Citation

Annals of Oncology (2024) 35 (suppl_1): S162-S204. 10.1016/annonc/annonc1482

Authors

W. Leijonmarck

Author affiliations

  • Karolinska Institutet, Huddinge/SE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 445P

Background

It is unknown if gastric adenocarcinoma survivors have longer, shorter, or similar survival compared to the background population. This knowledge could contribute to evidence-based monitoring strategies, healthcare recommendations, and information for patients and families.

Methods

This population-based cohort study included all patients who underwent gastrectomy for gastric adenocarcinoma between 2006-2015 in Sweden and survived ≥5 years after surgery who did not later die from tumour recurrence. They were followed up until death, postoperative year 10, or end of study period (31 December, 2020). Division of the observed by the expected survival yielded relative survival rates with 95% confidence intervals (CIs) using the life table method. The expected survival was derived from the entire Swedish population of the corresponding age, sex, and calendar year. Data came from medical records and nationwide registers.

Results

The survival among all 733 gastric adenocarcinoma survivors was shorter than the expected. The reduction in relative survival increased for each follow-up year, from 98.7% (95% CI: 97-100.5%) year 6 to 90.9% (95% CI: 86.7-95.2%) year 10. The decline in relative survival was more pronounced among patients who had gastrectomy in earlier calendar years (88.4% [95% CI: 83.0-93.9%] year 10 for years 2011-2015), shorter education (87.9% [95% CI: 80.1-95.7%] year 10 for education ≤9 years), more comorbidities (82.5% [95% CI: 68.2-96.7%] year 10 for Charlson comorbidity score ≥2), and no neoadjuvant therapy (87.7% [95% CI: 81.9-93.5%] year 10).

Conclusions

Gastric adenocarcinoma survivors seem to have poorer survival than the corresponding background population, particularly in certain subgroups.

Legal entity responsible for the study

Jesper Lagergren.

Funding

Swedish Research Council, Swedish Cancer Society, Stockholm Cancer Society.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.